Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | CALCR | P30988 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | GLP1R | P43220 | 4/20 | 0.50 |
| ▸ | SCTR | P47872 | 1/20 | 0.50 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29849560 | 0.98 | F2 (0.52) | F2CALCROPRM1OPRD1GLP1R | |
| SCHEMBL7628716 | 0.97 | F2 (0.51) | F2CALCROPRM1OPRD1GLP1R | |
| SCHEMBL7628730 | 0.97 | F2 (0.51) | F2CALCROPRM1OPRD1GLP1R | |
| SCHEMBL29798070 | 0.97 | F2 (0.55) | F2CALCRGLP1RSCTRTFPI | |
| SCHEMBL34460635 | 0.94 | CALCR (0.55) | F2CALCRGLP1RSCTRTFPI | |
| SCHEMBL31622472 | 0.94 | CALCR (0.55) | F2CALCRGLP1RSCTRTFPI | |
| SCHEMBL30746744 | 0.94 | CALCR (0.58) | F2CALCRGLP1RSCTRTFPI | |
| SCHEMBL31622473 | 0.93 | CALCR (0.55) | F2CALCRGLP1RSCTRTFPI | |
| SCHEMBL34460636 | 0.92 | CALCR (0.59) | F2CALCRGLP1RSCTRTFPI | |
| SCHEMBL38665433 | 0.90 | CALCR (0.54) | F2CALCROPRM1OPRD1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230018324-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF TYPE 1 DIABETES | DR. MARY MORRIS & ASSOCIATES, LLC (US) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551537-B2 | Methods and compositions for the treatment and prevention of type 1 diabetes | IAPP, GLP1R, SLC5A1 | F2 1724/4885CALCR 384/4885OPRM1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.